Bharat Parenterals’ subsidiary -- Innoxel Lifesciences has successfully cleared United States Food and Drug Administration (USFDA) inspection at its manufacturing facility in Vadodara, Gujarat.
The inspection was conducted from April 28, 2025 to May 2, 2025 and concluded with the issuance of a single minor observation under Form 483.
This outcome reflects Innoxel Lifesciences’ ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence across its manufacturing operations. The successful completion of this inspection further strengthens the company’s position in regulated markets and enhances its readiness to serve global customers with high-quality pharmaceutical products.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
